Braxia Scientific Featured in National News, W5 Canada's Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses

Rhea-AI Summary

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) is gaining media attention for its innovative ketamine treatments for depression. CEO Dr. Roger McIntyre is set to appear on CTV's W5 on October 23, 2021, discussing 'Psychedelic Healing'. The company was also featured in a Toronto Life article, highlighting ketamine's rapid effectiveness in treating mental disorders. Braxia operates clinics in major Canadian cities, aiming to alleviate the burden of brain-based mental illnesses.

Positive

• Increased media coverage enhances brand visibility and credibility.
• CEO Dr. Roger McIntyre's feature on a popular platform may attract new patients and investors.
• Highlighting the effectiveness of ketamine therapy could boost service demand.

Negative

• Dependence on regulatory approvals poses a risk to business operations.
• Potential side effects and legal complexities surrounding psychedelic treatments may deter some patients.

TORONTO, Oct. 22, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its inclusion in recent national and local news coverage of psychedelics to treat mental disorders.

Braxia Scientific CEO Dr. Roger McIntyre will be featured on CTV's W5, Canada's most-watched current affairs and documentary program. The episode, entitled "Psychedelic Healing," will air on Saturday, October 23, 2021, at 7 p.m. Eastern Time.

Braxia Scientific and the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned subsidiary, are also highlighted in a recent article by Toronto Life, a monthly magazine. In the piece, Dr. McIntyre and Dr. Joshua Rosenblat, Braxia Scientific's Chief Medical and Scientific Officer, discuss the benefits of ketamine therapy to rapidly treat mental disorders like treatment-resistant depression (TRD) and the access to the treatments Braxia Scientific provides through its clinics.

"A common outcome is not just the depression being gone," Dr. Rosenblat is quoted as saying, "but also actually being able to experience joy."

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD

"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre

Chairman & CEO

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/braxia-scientific-featured-in-national-news-w5-canadas-most-watched-documentary-series-providing-access-and-promoting-use-of-ketamine-to-treat-brain-based-illnesses-301406967.html

SOURCE Braxia Scientific Corp.

FAQ

What recent media coverage has Braxia Scientific received?

Braxia Scientific has been featured in CTV's W5 and in a Toronto Life article highlighting its ketamine treatments for mental disorders.

What is the significance of Dr. Roger McIntyre's appearance on CTV's W5?

Dr. McIntyre's appearance aims to raise awareness about the benefits of ketamine therapy in treating depression, potentially attracting more patients.

When will the CTV W5 episode featuring Braxia Scientific air?

The episode entitled 'Psychedelic Healing' will air on October 23, 2021, at 7 p.m. Eastern Time.

What services does Braxia Scientific offer?

Braxia Scientific provides innovative ketamine treatments for depression and related mental health disorders through its clinics in major Canadian cities.

What are the risks associated with Braxia Scientific's treatments?

Risks include regulatory hurdles and potential side effects from ketamine, which may affect patient uptake and treatment continuation.